TARGET CANCER: Premier Biomedical, Inc. and UTEP Proof of Concept Test Proves Successful, Accurate to Picogram Level

Premier Biomedical, Inc.William A. Hartman, CEO, 724-372-5242orBackground information:

Premier Biomedical, Inc. (OTC-BB: BIEI) has announced the successful outcome of a Proof of Concept Test performed by the University of Texas at El Paso (UTEP). This experiment targeted a specified Interleukin, implicated in the development of Cancer, for removal from a heterogeneous mixture. This test was completed successfully within minutes at the Picogram level (one trillionth of a gram).

In 2010, James Watson, co-discoverer of DNA and a winner of the 1962 Nobel Prize in Physiology or Medicine, stated to the Wall Street Journal that the selective removal of Interleukin from the blood would be a major victory in the War on Cancer. The experiment performed at the state-of-the-art UTEP Border Biomedical Research Center demonstrated that Premier Biomedical, Inc.’s proprietary methodology could remove Interleukin from a heterogeneous mixture with high precision, and without lowering the concentration of other molecules.

Premier Biomedical, Inc. CEO William Hartman has stated that the next step involved in proof of concept of this proprietary medical technology will be in vivo tests. UTEP is continuing proof of concept testing of Premier’s technology for Alzheimer’s disease, atherosclerosis, and traumatic brain injury (TBI).

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania. The Company’s common stock trades on the Over The Counter Bulletin Board under the ticker symbol “BIEI.”

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Suggested Articles

Merck CEO Ken Frazier and his colleagues vowed during the company's Investor Day that a healthy pipeline will drive margin expansion.

With the list of 34 drugs, the Chinese government is encouraging drugmakers to copy them under regulator's priority review pathway.

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.